Company News

MyoStrain® Provides Rapid, Accurate Assessment to Help Clinicians Detect Myocardial Ischemia and Rule Out Obstructive Coronary Artery Disease in Acute Chest Pain Patients

  • MyoStrain was utilized to rapidly rule out obstructive coronary artery disease in patients with acute chest pain, no history of significant coronary artery disease and inconclusive initial screening results
  • The article discusses MyoStrain’s potential to improve current clinical workflow efficiencies, highlighting the technology’s superior speed and sensitivity for evaluating cardiac patients
May 13, 2021
Company News

MORRISVILLE, N.C., May 13, 2021 – Myocardial Solutions (“MSI”) technologies MyoStrain® (fSENC) was featured in a newly published article exploring the effectiveness of cardiovascular magnetic resonance (CMR) and segmental strain to detect ischemia in patients suspected of obstructive coronary artery disease (CAD). It is the first study to evaluate CMR-based strain measurements for the identification of obstructive CAD in patients presented with acute chest pain. Results demonstrated MyoStrain’s significance as a quantitative heart function assessment providing clinicians with the speed and diagnostic accuracy to potentially improve clinical workflow efficiency and transform the detection and management of chest pain patients.[1]

The article further highlights MyoStrain’s clinical utility as a first-of-its-kind hyperventilation-based stress test. Called MyoStress, the new protocol would enable a green and needle-free assessment without the use of pharmacological stressors to help rule-in and rule-out chest pain patients based on their individual cardiac risk.[2]

Professor Matthias Friedrich, MD, FESC, FACC, MSCMR, Professor of Medicine and Chief of Cardiovascular Imaging at McGill University Health Centre in Montreal, Quebec, commented about MyoStrain on Twitter: “Fast CMR strain imaging (MyoStrain) in acute coronary syndrome. No adenosine, no dobutamine. Better than ECG, better than troponin.”

John Funkhouser, CEO at MSI, stated: “These are significant findings because about 12% of all emergency patients arrive with symptoms of chest pain. This article shows that MyoStrain may provide a far more sensitive and accurate tool to help clinicians quickly rule out obstructive CAD compared to the current standard of care, such as ECG, troponin and traditional imaging modalities. Furthermore, MyoStrain’s speed could help to significantly improve clinical workflow and efficiency inside the ER, streamlining care to the benefit of both patients and physicians.”

 Access to the publication is available here.

[1] Riffel JH, Siry D, Salatzki J, Andre F, Ochs M, Weberling LD, et al. (2021) Feasibility of fast cardiovascular magnetic resonance strain imaging in patients presenting with acute chest pain. PLoS ONE 16(5): e0251040. https://doi.org/10.1371/journal.pone.0251040

[2] Ochs, Met al. J Am Coll Cardiol Cardiovasc Imaging.Apr 14, 2021. DOI: 10.1016/j.jcmg.2021.02.022

Media Contact

Ahmed Osman
PR@myocardialsolutions.com
919.459.9113 

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.